Blog

On 18 October 2024, our colleague Wanze Zhang successfully gave a presentation on ‘Current situation of European patent infringement litigation and new progress in supplementary protection certificates’ during the 9th IP Forefront Pharma Forum 2024 in Suzhou, China.

In the ongoing dispute over 3D medical imaging systems, the French company QuantifiCare has regained the upper hand against Canfield Scientific: With the help of our our partner Dr Dirk Schulz and his colleague Dr Felix Klopmeier from Lang & Rahmann they succeeded in nullity proceedings

We are thrilled to announce that our partner, Wasilis Koukounis, has been recognized as a "Rising Star" by Managing IP, one of the leading platforms in the field of intellectual property. This prestigious recognition is a testament to ...

Are you risking your entire drug patent strategy with one simple oversight? Dosage regimen patents have become a minefield for pharmaceutical companies, with even the smallest misstep leading to costly rejections. Whether you're struggling to navigate the EPO's inventive step requirements or facing setbacks from clinical trial disclosures, securing a strong dosage patent has never been more challenging. But why are so many companies still getting it wrong? And what crucial strategies are being overlooked in jurisdictions like the UK and US? Keep reading as we reveal the hidden pitfalls and insider tips that could make or break your next dosage regimen patent.